Sencyr®

About S-biomedic

S-Biomedic is a pioneering private biotech company developing live skin probiotics and postbiotics derived from the skin's most abundant bacterium, Cutibacterium acnes. The company's platform aims to treat conditions like acne by modulating the skin microbiome to restore its natural, healthy balance, moving beyond conventional dermatological treatments. It has validated its approach through over 15 clinical studies and has established a significant partnership with Beiersdorf, which recently acquired the company. S-Biomedic's first commercial program, Sencyr®, is a microbiome care system for acne-prone skin.

Therapeutic Areas